<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="publisher-id">RSX</journal-id><journal-id journal-id-type="hwp">sprsx</journal-id><journal-id journal-id-type="nlm-ta">Reprod Sci</journal-id><journal-title>Reproductive Sciences</journal-title><issn pub-type="ppub">1933-7191</issn><issn pub-type="epub">1933-7205</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1177/1933719112459227</article-id><article-id pub-id-type="publisher-id">10.1177_1933719112459227</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effects of Angiogenic Factors, Antagonists, and Podocyte Injury on Development of Proteinuria in Preeclampsia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Guixiang</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1-1933719112459227">1</xref><xref ref-type="aff" rid="aff2-1933719112459227">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lihong</given-names></name><degrees>MM</degrees><xref ref-type="aff" rid="aff1-1933719112459227">1</xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Xiaohong</given-names></name><degrees>MM</degrees><xref ref-type="aff" rid="aff1-1933719112459227">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yunjiao</given-names></name><degrees>MM</degrees><xref ref-type="aff" rid="aff1-1933719112459227">1</xref></contrib><contrib contrib-type="author"><name><surname>Niu</surname><given-names>Jianying</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1-1933719112459227">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jing</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff3-1933719112459227">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gu</surname><given-names>Yong</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1-1933719112459227">1</xref><xref ref-type="aff" rid="aff3-1933719112459227">3</xref><xref ref-type="corresp" rid="corresp1-1933719112459227"/></contrib></contrib-group><aff id="aff1-1933719112459227"><label>1</label>Division of Nephrology, The Fifth People’s Hospital of Shanghai, Fudan University, Shanghai, China</aff><aff id="aff2-1933719112459227"><label>2</label>Division of Nephrology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China</aff><aff id="aff3-1933719112459227"><label>3</label>Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China</aff><author-notes><corresp id="corresp1-1933719112459227">Yong Gu, No. 801, HeQing Road, MinHang District, Shanghai 200240, People’s Republic of China. Email: <email>yonggu@vip.163.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>5</month><year>2013</year></pub-date><volume>20</volume><issue>5</issue><fpage>579</fpage><lpage>588</lpage><permissions><copyright-statement>© The Author(s) 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder content-type="society">Society for Gynecologic Investigation</copyright-holder></permissions><abstract><p>Proteinuria is universal to all patients with preeclampsia. We examined the urinary podocytes in women with preeclampsia (n = 14), gestational hypertension (n = 14), and normal pregnancy. Maternal serum and urinary concentrations of vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and the antiangiogenic factor soluble fms-like tyrosine kinase 1 (sFlt-1) were detected. These concentrations were used to evaluate the urinary excretion of podocytes and the alteration of angiogenic factors and to assess their relationships to proteinuria in preeclampsia. Our studies suggest that the urinary podocyte number and angiogenic factors are correlated with random urine albumin/creatinine ratio and blood pressure. Receiver–operating characteristic (ROC) curves of serum and urinary PlGF and the PlGF/sFlt-1 ratio as well as the presence of podocyturia confirmed their usefulness in distinguishing preeclamptic and normotensive pregnant women. In addition, combinations of serum or urinary PlGF or podocyturia tests in parallel or in series provided the best clue for identifying patients with preeclampsia. We considered that the dysregulation of angiogenic factors and its subsequent podocyte injury may contribute to the mechanism of proteinuria development in preeclampsia.</p></abstract><kwd-group><kwd>angiogenic factors</kwd><kwd>preeclampsia</kwd><kwd>proteinuria</kwd><kwd>podocyte</kwd></kwd-group></article-meta></front><body><sec id="section1-1933719112459227"><title>Introduction</title><p>Preeclampsia is a pregnancy-specific disorder affecting at least 5% of all pregnancies worldwide and is thus becoming a major health concern.<sup><xref ref-type="bibr" rid="bibr1-1933719112459227">1</xref></sup> Among the maternal pathologic hallmarks, which include hypertension, proteinuria, and edema, the most distinctive hallmark of preeclampsia is proteinuria, a reflection of renal injury. However, the causes of preeclampsia are still obscure.</p><p>It has been extensively accepted that the proteins lining the podocyte slit diaphragms play a critical role in the maintenance of glomerular permeability.<sup><xref ref-type="bibr" rid="bibr2-1933719112459227">2</xref></sup> Recently, the downregulation of podocyte foot process proteins has garnered particular attention in the development of proteinuria in preeclampsia.<sup><xref ref-type="bibr" rid="bibr2-1933719112459227">2</xref>,<xref ref-type="bibr" rid="bibr3-1933719112459227">3</xref></sup> Additionally, urinary podocyte excretion is related to the podocyte injury observed in various renal diseases and is associated with disease activity as well as severity.<sup><xref ref-type="bibr" rid="bibr4-1933719112459227">4</xref><xref ref-type="bibr" rid="bibr5-1933719112459227"/><xref ref-type="bibr" rid="bibr6-1933719112459227"/>–<xref ref-type="bibr" rid="bibr7-1933719112459227">7</xref></sup> Podocalyxin, a podocyte-specific sialoprotein, has been used for urinary podocyte diagnostics.<sup><xref ref-type="bibr" rid="bibr8-1933719112459227">8</xref></sup> Several studies have also revealed that podocyturia is present in preeclampsia.<sup><xref ref-type="bibr" rid="bibr9-1933719112459227">9</xref><xref ref-type="bibr" rid="bibr10-1933719112459227"/>–<xref ref-type="bibr" rid="bibr11-1933719112459227">11</xref></sup> The factors that cause podocyte injury in preeclampsia are poorly understood.</p><p>Numerous researchers have focused on angiogenic factors secreted by the ischemic placenta, which is partly responsible for the maternal syndrome in pregnancy.<sup><xref ref-type="bibr" rid="bibr12-1933719112459227">12</xref><xref ref-type="bibr" rid="bibr13-1933719112459227"/><xref ref-type="bibr" rid="bibr14-1933719112459227"/>–<xref ref-type="bibr" rid="bibr15-1933719112459227">15</xref></sup> These factors include vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and their antagonist, soluble fms-like tyrosine kinase 1 (sFlt-1). We propose that the imbalance of angiogenic factors and their antagonist, sFlt-1, may contribute to podocyte injury and subsequent proteinuria. This study was designed to evaluate the urinary excretion of podocytes in preeclampsia and the alterations of VEGF, PlGF, and sFlt-1. In addition, we aimed to assess the relationships of these factors to proteinuria as well as their diagnostic sensitivity and specificity.</p></sec><sec id="section2-1933719112459227"><title>Participants and Methods</title><sec id="section3-1933719112459227"><title>Participants</title><p>From March 2009 to March 2010, women with preeclampsia (n = 14), gestational hypertension (n = 14), and gestational age-matched normotensive pregnant women (n = 13) were recruited from the Department of Gynecology and Obstetrics, The Fifth People’s Hospital of Shanghai, Fudan University, China. Preeclampsia was defined as a systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg after 20 weeks of gestation accompanied by proteinuria &gt;1 + by dipstick in a random urine analysis or ≥300 mg/24 h with no evidence of urinary tract infection. Gestational hypertension was defined as a systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg after 20 weeks of gestation in the absence of significant proteinuria (≤1 + by dipstick or &lt;300 mg/24 h).<sup><xref ref-type="bibr" rid="bibr16-1933719112459227">16</xref></sup> These patients enrolled in this study were all newly admitted inpatients and all samples were collected before any medication. Women with diabetes mellitus, thyroid, liver, or chronic renal disease, or preexisting chronic hypertension were excluded from the study. The study was approved by the local ethics committee before the experiment was started and followed the ethical standards of the Helsinki Declaration. All participants provided written informed consent to participate in the study.</p></sec><sec id="section4-1933719112459227"><title>Immunofluorescence for the Quantification of Urinary Podocytes</title><p>The quantification of urinary podocytes was performed as previously reported.<sup><xref ref-type="bibr" rid="bibr17-1933719112459227">17</xref>,<xref ref-type="bibr" rid="bibr18-1933719112459227">18</xref></sup> Fresh first void morning urine (50-100 mL) was collected for 3 consecutive days within 1 week before labor, and the number of urinary podocytes was counted daily. No special drugs that impact on the urinary samples were used during the course for more than 1 week before delivery. Each urine specimen was centrifuged at 1000 g for 5 minutes within 30 minutes after voiding. One-half milliliter of phosphate-buffered saline (PBS), pH 7.2, was used to wash and resuspend the sediment. The sample was then centrifuged for 5 minutes at 1000<italic>g</italic> onto poly-<sc>l</sc>-lysine–coated glass slides using cytospin (TXT3; Shanghai Lu Xiangyi Centrifuge Instrument Co, Ltd, Shanghai, China) . The slides were air-dried and fixed in acetone for 5 minutes at 4°C. The urinary sediment was incubated with antihuman podocalyxin monoclonal antibody (R&amp;D Systems Inc, Minneapolis, Minnesota) at 10 μg/mL for 60 minutes at 37°C. Then the slides were incubated with Cy2-labeled anti-mouse immunoglobulin G (IgG; United Chemicon Inc, Rosemont, Illinois) at a dilution of 1:100 for 30 minutes at 37°C. Cell nuclei were counterstained with Hoechst 33342 (Sigma-Aldrich Corp, Carlsbad, California) for 5 minutes at a concentration of 5 μg/mL. Immunofluorescence microscopy was used to examine the slides. Cells staining positive for both podocalyxin and nuclei were defined as entire podocytes. The number of urinary podocytes was expressed as cells/mL and was reported as the average number of podocytes from 3 samples for each individual. Two of the authors were engaged in the blinded quantitative analysis. The random urine albumin/creatinine ratio (ACR), which strongly correlates with the 24-hour urine protein excretion, was also estimated.<sup><xref ref-type="bibr" rid="bibr4-1933719112459227">4</xref></sup></p></sec><sec id="section5-1933719112459227"><title>Enzyme-Linked Immunosorbent Assays</title><p>Maternal fasting blood samples and fresh first void morning urine samples were collected before labor for this assay. The serum was centrifuged within 30 minutes of collection at 3000<italic>g</italic> for 10 minutes, and the urinary samples were centrifuged at 2000<italic>g</italic> for 10 minutes, immediately thereafter, the serum and the clear supernatants were frozen at −80°C and stored for less than 12 months. The samples were thawed only once for this study. Serum and urinary VEGF (4A Biotech, Beijing), PlGF (Rapidbio Inc Shanghai LangKa Trade Co, Ltd, Shanghai, China), and sFlt-1 (Rapidbio Inc) concentrations were measured with commercially available enzyme-linked immunosorbent assays (ELISAs) performed in duplicate according to the manufacturers’ instructions. The minimal detectable doses of VEGF, PlGF, and sFlt-1 were 7, 2.5, and 20 pg/mL, respectively. The interassay and intra-assay coefficients of variation were all less than 10%. The correlation coefficient of the standard curves was &gt;.99.</p></sec><sec id="section6-1933719112459227"><title>Statistical Analysis</title><p>The SPSS 13.0 was used for all statistical analyses. All normally distributed parameters were each expressed as the mean ± SD, and the skewed distributed parameters were each expressed as the median (interquartile range; [IQR]). One-way analyses of variance (ANOVAs) between groups and Student-Newman-Keuls (SNK-q) were used to compare normally distributed data. The Mann-Whitney <italic>U </italic>test was used for the comparison of nonnormally distributed parameters. Pearson and Spearman correlations were used for parametric data and nonparametric data, respectively. Receiver–operating characteristic (ROC) curves were plotted, and the area under the curve (AUC) was analyzed. All <italic>P</italic> values were 2-tailed, and <italic>P</italic> &lt; .05 was defined as statistically significant.</p></sec></sec><sec id="section7-1933719112459227"><title>Results</title><sec id="section8-1933719112459227"><title>Clinical Profiles of the Participants</title><p>The demographical and clinical data of the patients are presented in <xref ref-type="table" rid="table1-1933719112459227">Table 1</xref>. Compared with the normal pregnancy group, blood pressure was significantly higher in women with preeclampsia and gestational hypertension. The gestational age was shorter, and the infant birth weights were lower in women with preeclampsia. Additionally, blood urea nitrogen (BUN), serum creatinine, uric acid, ACR, and proteinuria were significantly higher, while the estimated glomerular filtration rate (eGFR) and the creatinine clearance were lower in women with preeclampsia than in other 2 groups. However, it should be noted that despite this difference, the BUN and the serum creatinine values were still within the normal range in all 3 groups. The uric acid was also slightly higher, and the eGFR was lower in women with gestational hypertension than in those with normal pregnancies. No significant differences in other demographical data were observed.</p><table-wrap id="table1-1933719112459227" position="float"><label>Table 1.</label><caption><p>Clinical Profiles and Laboratory Data.</p></caption><graphic alternate-form-of="table1-1933719112459227" xlink:href="10.1177_1933719112459227-table1.tif"/><table><thead><tr><th>Characteristic Normal Pregnancy</th><th>Normal Pregnancy (n = 13)</th><th>Preeclampsia (n = 14)</th><th>Gestational Hypertension (n = 14)</th></tr></thead><tbody><tr><td>Age, years</td><td>26.00 ± 1.63</td><td>29.64 ± 4.80</td><td>27.21 ± 5.41</td></tr><tr><td>Body mass index, kg/m</td><td>26.90 ± 2.36</td><td>27.71 ± 3.78</td><td>29.17 ± 2.45</td></tr><tr><td>Blood pressure, mm Hg</td><td/><td/><td/></tr><tr><td> Systolic</td><td>117.31 ± 9.04</td><td>150.71 ± 19.30<sup>d</sup></td><td>146.21 ± 9.36<sup>d</sup></td></tr><tr><td> Diastolic</td><td>74.23 ± 5.72</td><td>98.21 ± 8.68<sup>d</sup></td><td>96.29 ± 7.78<sup>d</sup></td></tr><tr><td>Gestational age at delivery, week</td><td>39.67 ± 2.57</td><td>36.77 ± 2.94<sup>d</sup></td><td>39.50 ± 1.30</td></tr><tr><td>Birth weight of infants, g</td><td>3578.08 ± 297.84</td><td>2655.83 ± 651.21<sup>d</sup></td><td>3394.29 ± 367.68</td></tr><tr><td>Bood urea nitrogen, mmol/L</td><td>2.92 ± 7.26</td><td>5.03 ± 2.33<sup>c</sup></td><td>2.83 ± 1.03</td></tr><tr><td>Creatinine, μmol/L</td><td>44.38 ± 9.10</td><td>54.79 ± 12.58<sup>c</sup></td><td>44.08 ± 7.34</td></tr><tr><td>Uric acid, μmol/L</td><td>230.77 ± 65.29</td><td>391.57 ± 134.78<sup>d</sup></td><td>298.15 ± 87.52<sup>b</sup></td></tr><tr><td>eGFR(MDRD), mL/min/1.73m<sup><xref ref-type="bibr" rid="bibr2-1933719112459227">2</xref></sup></td><td>197.32 ± 50.69</td><td>117.94 ± 36.31<sup>d</sup></td><td>158.10 ± 32.67<sup>b</sup></td></tr><tr><td>Creatinine clearance (mL/min)</td><td>191.65 ± 42.16</td><td>155.31 ± 42.58<sup>b</sup></td><td>206.78 ± 43.96</td></tr><tr><td>ACR, mg/g, median (IQR)</td><td>15.95 (7.37, 32.75)</td><td>257.97 (93.11, 729.64)<sup>d</sup></td><td>9.88 (2.63, 24.43)</td></tr><tr><td>Proteinuria (qualitation)</td><td align="center">Negative</td><td align="center">2+ ∼ 4+</td><td align="center">Negative / 1+</td></tr><tr><td>Proteinuria, g/24 h</td><td align="center">No data</td><td align="center">2.391(0.815, 7.331)</td><td align="center">0.175(0.163, 0.254)<sup>e</sup></td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-1933719112459227"><p>Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; ACR, urine albumin/creatinine ratio; IQR, interquartile range.</p></fn><fn id="table-fn2-1933719112459227"><p><sup>a</sup> Negative, the 24-hour urine protein excretion in women with normal pregnancy was presumed to 150 mg (it should be &lt;150 mg in normal pregnancy). It was used for the following correlation analysis: <sup>b</sup> <italic>P </italic>&lt; .05, <sup>c</sup> <italic>P </italic>&lt; .01, <sup>d</sup> <italic>P </italic>&lt; .001 compared to normal pregnancy; <sup>e</sup> <italic>P </italic>&lt; .001 compared to the preeclampsia group.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section9-1933719112459227"><title>Levels of Urinary Podocyte</title><p>Positive immunofluorescent staining using antihuman podocalyxin antibodies and nuclear counterstaining were used to identify intact podocytes (<xref ref-type="fig" rid="fig1-1933719112459227">Figure 1</xref>). The number of urinary podocytes in women with preeclampsia (median: 3.10 cells/mL, <italic>P </italic>&lt; .001) and gestational hypertension (1.41 cells/mL, <italic>P </italic>&lt; .05) was significantly higher than that in normal pregnancy (0.52 cells/mL). Furthermore, this number was significantly higher in women with preeclampsia than in women in the gestational hypertension group (<italic>P </italic>&lt; .05; <xref ref-type="fig" rid="fig2-1933719112459227">Figure 2</xref>).</p><fig id="fig1-1933719112459227" position="float"><label>Figure 1.</label><caption><p>Urinary podocytes examined by immunofluorescence using antihuman podocalyxin antibody. The nuclei were stained by Hoechst 33342 (×200). The cells directed by arrows are intact podocytes in urine.</p></caption><graphic xlink:href="10.1177_1933719112459227-fig1.tif"/></fig><fig id="fig2-1933719112459227" position="float"><label>Figure 2.</label><caption><p>Comparison of podocyturia levels among normal pregnancies and patients. The results, expressed as the number of urinary podocyte in 1 mL urine, demonstrate that the number of urinary podocytes in preeclampsia significantly increased. The data are shown as medians (interquartile ranges). *<italic>P </italic>&lt; .05, ***<italic>P </italic>&lt; .001 vs normal pregnancy group; <sup>#</sup><italic>P </italic>&lt; .05 vs gestational hypertension group.</p></caption><graphic xlink:href="10.1177_1933719112459227-fig2.tif"/></fig></sec><sec id="section10-1933719112459227"><title>Serum and Urinary VEGF, PlGF, and sFlt-1 Concentration Detection as well as Serum and Urinary PlGF/sFlt-1 Ratio</title><p>As shown in <xref ref-type="fig" rid="fig3-1933719112459227">Figure 3</xref> (A, B, and C), serum VEGF concentrations in women with preeclampsia (44.05 ± 25.01 pg/mL) were higher than in women with normal pregnancies (25.84 ± 14.22 pg/mL, <italic>P</italic> &lt; .05) or gestational hypertension (34.75 ± 15.67 pg/mL, <italic>P </italic>&gt; .05). Urinary VEGF concentrations did not differ significantly among the 3 groups. Serum and urinary PlGF concentrations in women with preeclampsia (serum: 52.59 ± 7.46; urine: 12.39 ± 5.30 pg/mL) were significantly lower than in women with gestational hypertension (serum: 60.39 ± 4.74, <italic>P </italic>= .001; urine: 26.25 ± 8.25 pg/mL, <italic>P </italic>&lt; .05) or normal pregnancies (serum: 65.40 ± 3.76, <italic>P </italic>&lt; .001; urine: 31.81 ± 26.65 pg/mL, <italic>P </italic>&lt; .01). Serum PlGF concentrations in women with gestational hypertension were also significantly lower than in women with normal pregnancies (<italic>P </italic>&lt; .05), and urinary PlGF concentrations did not differ significantly between women with gestational hypertension and those with normal pregnancies. Serum and urinary sFlt-1 concentrations in women with preeclampsia (serum: 538.33 ± 53.28, <italic>P </italic>&lt; .05; urine: 812.09 ± 75.78 pg/mL, <italic>P </italic>&lt; .01) and gestational hypertension (serum: 546.11 ± 66.80, <italic>P </italic>&lt; .05; urine: 813.34 ± 68.03 pg/mL, <italic>P </italic>&lt; .01) were significantly higher than in women with normal pregnancies (serum: 466.82 ± 111.57; urine: 679.35 ± 188.88 pg/mL). We then analyzed the serum and urinary PlGF/sFlt-1 ratios (<xref ref-type="fig" rid="fig3-1933719112459227">Figure 3D</xref>). The serum and urinary PlGF/sFlt-1 ratios in women with preeclampsia (serum: <italic>P</italic> &lt; .001; urine: <italic>P</italic> &lt; .01) and gestational hypertension (serum: <italic>P</italic> &lt; .001; urine: <italic>P</italic> &lt; .05) were significantly lower than in women with normal pregnancies, and the ratios were slightly lower in women with preeclampsia compared to those with gestational hypertension, although the difference was not statistically significant.</p><fig id="fig3-1933719112459227" position="float"><label>Figure 3.</label><caption><p>The concentration of serum and urinary VEGF (A), PlGF (B), and sFlt-1(C) as well as the PlGF/ sFlt-1 ratio (D) in women with normal pregnancies and in patients with hypertension or preeclampsia. The data are shown as the means ± SEs *<italic>P </italic>&lt; .05, **<italic>P </italic>&lt; .01, ***<italic>P </italic>≤ .001. VEGF indicates vascular endothelial growth factor; PlGF, placental growth factor; sFlt-1, antiangiogenic factor soluble fms-like tyrosine kinase 1.</p></caption><graphic xlink:href="10.1177_1933719112459227-fig3.tif"/></fig></sec><sec id="section11-1933719112459227"><title>Relationships Among Clinical Profiles, Podocyturia, and Proangiogenic and Antiangiogenic Factors</title><p>The analysis of the correlation among renal function, proteinuria (ACR), podocyturia, and the serum and urinary levels of VEGF, PlGF, sFlt-1, and the PlGF/sFlt-1 ratios are shown in <xref ref-type="table" rid="table2-1933719112459227">Table 2</xref>. There was a positive correlation between podocyturia and ACR, BUN, UA, SBP, and DBP as well as a negative correlation between podocyturia and eGFR. We also identified a significantly positive correlation between serum VEGF and podocyturia, ACR, UA, SBP, DBP as well as a negative correlation between serum VEGF and eGFR (<italic>P</italic> &lt; .05). Serum PlGF levels negatively correlated with podocyturia, ACR, BUN, UA, SBP, and DBP but positively correlated with eGFR. Urinary PlGF was inversely associated with ACR. Urinary sFlt-1 positively correlated with blood pressure. In addition, the serum PlGF/sFlt-1 ratio was inversely correlated with podocyturia, ACR, UA, SBP, and DBP. The urinary PlGF/sFlt-1 ratio correlated inversely with ACR.</p><table-wrap id="table2-1933719112459227" position="float"><label>Table 2.</label><caption><p>Relationships Among Clinical Profiles, Podocyturia, Angiogenic Factors, and Antiangiogenic Factors as Assessed by Pearson or Spearman Correlation Coefficients.<sup>a,b</sup></p></caption><graphic alternate-form-of="table2-1933719112459227" xlink:href="10.1177_1933719112459227-table2.tif"/><table><thead><tr><th rowspan="2">Parameter</th><th colspan="8">r/ P Value (n = 41)</th></tr><tr><th>Podocyturia</th><th>ACR</th><th>BUN</th><th>SCr</th><th>UA</th><th>eGFR</th><th>SBP</th><th>DBP</th></tr></thead><tbody><tr><td>Podocyturia</td><td>1</td><td>.631/&lt;.001</td><td>.465/.005</td><td>.291/.090</td><td>.472/.004</td><td>−.387/.024</td><td>.534/0.001</td><td>.559/&lt;.001</td></tr><tr><td>Serum VEGF</td><td>.520/.002</td><td>.506/.001</td><td>.193/.246</td><td>.273/.098</td><td>.432/.007</td><td>−.334/.016</td><td>.528/0.001</td><td>.403/.011</td></tr><tr><td>UrinaryVEGF</td><td>−.148/.404</td><td>.169/.305</td><td>−.032/.849</td><td>−.031/.855</td><td>.004/.981</td><td>.138/.415 </td><td>−.098/.552</td><td>−.224/.170</td></tr><tr><td>Serum PlGF</td><td>−.427/.009</td><td>−.407/.008</td><td>−.360/.023</td><td>−.266/.097</td><td>−.442/.004</td><td>.395/.013</td><td>−.543/&lt;.001</td><td>−.581/&lt;.001</td></tr><tr><td>Urinary PlGF</td><td>−.228/.180</td><td>−.326/.037</td><td>−.248/.122</td><td>−.046/.777</td><td>−.278/.082</td><td>−.027/.871</td><td>−.280/.076</td><td>−.214/.179</td></tr><tr><td>Serum sFlt-1</td><td>.319/.058</td><td>.079/.624</td><td>.015/.926</td><td>.057/.727</td><td>.223/.166</td><td>−.100/.545</td><td>.168/.294</td><td>.220/.166</td></tr><tr><td>Urinary sFlt-1</td><td>.308/.068</td><td>−.014/0.929</td><td>.114/.485</td><td>.000/.998</td><td>.219/.174</td><td>−.016/.923</td><td>.385/.013</td><td>.327/.037</td></tr><tr><td>Serum PlGF/ sFlt-1</td><td>−.540/.001</td><td>−.392/0.011</td><td>−.222/.169</td><td>−.166/.305</td><td>−.434/.005</td><td>.256/.116</td><td>−.451/.003</td><td>−.498/.001</td></tr><tr><td>Urinary PlGF/ sFlt-1</td><td>−.269/.113</td><td>−.333/.034</td><td>−.206/.201</td><td>−.113/0.487</td><td>−.272/0.089</td><td>−.033/.842</td><td>−.167/.296</td><td>−.051/.750</td></tr></tbody></table></table-wrap><p>Furthermore, there was a significant correlation between serum and urinary VEGF, PlGF, sFlt-1, and the PlGF/sFlt-1 ratio (<xref ref-type="fig" rid="fig4-1933719112459227">Figure 4A</xref>-D). Serum PlGF was positively correlated with urinary PlGF (<italic>r</italic>/<italic>P</italic>: .342/.028), and serum sFlt-1 was positively correlated with urinary sFlt-1 (<italic>r</italic>/<italic>P</italic>: .624/&lt;.001). The serum PlGF/sFlt-1 ratio was positively correlated with the urinary PlGF/sFlt-1 ratio (<italic>r</italic>/<italic>P</italic>: .805/&lt;.001). Urinary PlGF was inversely correlated with urinary sFlt-1 (<italic>r</italic>/<italic>P</italic>: −.721/&lt;.001).</p><fig id="fig4-1933719112459227" position="float"><label>Figure 4.</label><caption><p>The relationship between the concentrations of serum and urinary PlGF (A), between the concentrations of serum and urinary sFlt-1 (B), and between the serum and urinary PlGF/sFlt-1 ratios (C) as well as the relationship between the concentration of urinary PlGF and urinary sFlt-1 in all participants. VEGF indicates vascular endothelial growth factor; PlGF, placental growth factor; sFlt-1, antiangiogenic factor soluble fms-like tyrosine kinase 1.</p></caption><graphic xlink:href="10.1177_1933719112459227-fig4.tif"/></fig><p>Collectively, podocyturia was closely correlated with proteinuria, renal function, and blood pressure. Furthermore, serum angiogenic factors and the serum PlGF/sFlt-1 ratio were also closely correlated with podocyturia, renal function, and blood pressure.</p></sec><sec id="section12-1933719112459227"><title>Usefulness of Podocyturia, Angiogenic Factors, and Antiangiogenic Factors for the Identification of Preeclampsia and Normal Pregnancy</title><p>To assess the use of podocyturia, angiogenic factors, and antiangiogenic factors for identifying preeclampsia and normotensive pregnancies, the ROC curves were plotted (<xref ref-type="fig" rid="fig5-1933719112459227">Figure 5A</xref>-E). The AUC of podocyturia, 0.868 (95% CI: 0.751-0.985, <italic>P </italic>&lt; .001), was greater than that of VEGF (serum: 0.675; 95% CI, 0.483-0.866, <italic>P</italic> = .079 and urine: 0.550; 95% CI, 0.354-0.746, <italic>P</italic> = .613) or sFlt-1 (serum: 0.590; 95% CI, 0.414-0.766, <italic>P</italic> = .350 and urine: 0.567; 95% CI, 0.383-0.752, <italic>P</italic> = .483) but was comparable to that of PlGF (serum: 0.872; 95% CI, 0.744-1.000, <italic>P</italic> &lt; .001 and urine: 0.811; 95% CI, 0.681-0.941, <italic>P</italic> = .001) and the PlGF/sFlt-1 ratio (serum: 0.847; 95% CI, 0.728-0.965, <italic>P</italic> &lt; .001 and urine: 0.815; 95% CI, 0.686-0.943, <italic>P</italic> = .001). In summary, podocyturia, serum and urinary PlGF, and the PlGF/sFlt-1 ratio are very useful for distinguishing preeclampsia and normal pregnancy.</p><fig id="fig5-1933719112459227" position="float"><label>Figure 5.</label><caption><p>The ROC curve of the number of urinary podocytes (A), the concentrations of serum and urinary VEGF (B), PlGF (C), and sFlt-1(D) and the PlGF/ sFlt-1 ratio (E) for the identification of preeclampsia. The AUC of podocyturia is 0.868 (95% CI: 0.751-0.985, <italic>P</italic> &lt; .001); the AUC of serum and urinary VEGF is 0.675 (95% CI, 0.483-0.866, <italic>P</italic> = .079) and 0.550 (95% CI, 0.354-0.746, <italic>P</italic> = .613) respectively; the AUC of serum and urinary PlGF is 0.872 (95% CI, 0.744-1.000, <italic>P</italic> &lt; .001) and 0.811 (95% CI, 0.681-0.941, <italic>P</italic> = .001), respectively; the AUC of serum and urinary sFlt-1 is 0.590 (95% CI, 0.414-0.766, <italic>P</italic> = .350) and 0.567 (95% CI, 0.383-0.752, <italic>P</italic> = .483), respectively; the AUC of the serum and urinary PlGF/sFlt-1 ratio is 0.847 (95% CI, 0.728-0.965, <italic>P</italic> &lt; .001) and 0.815 (95% CI, 0.686-0.943, <italic>P </italic>= .001), respectively. Null hypothesis: true area = 0.5. VEGF indicates vascular endothelial growth factor; PlGF, placental growth factor; sFlt-1, antiangiogenic factor soluble fms-like tyrosine kinase 1; ROC, receiver–operating characteristics.</p></caption><graphic xlink:href="10.1177_1933719112459227-fig5.tif"/></fig><p>In addition, the sensitivity, specificity, and other evaluation parameters were evaluated. Using different cutoff values, podocyturia, PlGF and the PlGF/sFlt-1 ratio exhibited different sensitivities, specificities, and other evaluation parameters for the diagnosis of preeclampsia (<xref ref-type="table" rid="table3-1933719112459227">Tables 3</xref><xref ref-type="table" rid="table4-1933719112459227"/><xref ref-type="table" rid="table5-1933719112459227"/><xref ref-type="table" rid="table6-1933719112459227"/>–<xref ref-type="table" rid="table7-1933719112459227">7</xref>). The cutoff point with the highest Youden’s index was defined as the optimized cutoff value. In this context, serum PlGF &lt;60 pg/mL, urinary PlGF &lt;25 pg/mL, and podocyturia ≥1 cells/mL were determined to combine in parallel or in series differently. These combinations may provide clue for future studies about the early diagnosis of preeclampsia (<xref ref-type="table" rid="table8-1933719112459227">Table 8</xref>). The PlGF/sFlt-1 ratio in the serum (&lt;0.12) or in urine (&lt;0.025) had the maximal diagnostic value.</p><table-wrap id="table3-1933719112459227" position="float"><label>Table 3.</label><caption><p>Different Cutoff Points for Podocyturia and the Evaluated Index for Preeclampsia Diagnosis.</p></caption><graphic alternate-form-of="table3-1933719112459227" xlink:href="10.1177_1933719112459227-table3.tif"/><table><thead><tr><th>Cutoff Points, Cells/mL</th><th>Sensitivity, %</th><th>Specificity, %</th><th>Positive Predictive Value, %</th><th>Negative Predictive Value, %</th><th>Agreement Rate, %</th><th>Youden Index, <italic>r</italic></th><th>Positive LR</th><th>Negative LR</th></tr></thead><tbody><tr><td>0.6</td><td>100</td><td>53.85</td><td>70.00</td><td>100</td><td>77.78</td><td>0.54</td><td>2.17</td><td>0</td></tr><tr><td>0.8</td><td>100</td><td>61.54</td><td>73.68</td><td>100</td><td>81.48</td><td>0.62</td><td>2.60</td><td>0</td></tr><tr><td>1.0</td><td>100</td><td>76.92</td><td>82.35</td><td>100</td><td>88.89</td><td>0.77</td><td>4.33</td><td>0</td></tr><tr><td>2.0</td><td>85.71</td><td>84.62</td><td>85.71</td><td>84.62</td><td>85.19</td><td>0.70</td><td>5.57</td><td>0.17</td></tr><tr><td>3.0</td><td>57.14</td><td>100</td><td>100</td><td>68.42</td><td>77.78</td><td>0.57</td><td align="center">—</td><td>0.43</td></tr></tbody></table><table-wrap-foot><fn id="table-fn4-1933719112459227"><p>Abbreviation: LR, likelihood ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table4-1933719112459227" position="float"><label>Table 4.</label><caption><p> Different Cutoff Points for Serum PlGF and the Evaluated Index for Preeclampsia Diagnosis.</p></caption><graphic alternate-form-of="table4-1933719112459227" xlink:href="10.1177_1933719112459227-table4.tif"/><table><thead><tr><th>Cutoff Points, Cells/mL</th><th>Sensitivity, %</th><th>Specificity, %</th><th>Positive Predictive Value, %</th><th>Negative Predictive Value, %</th><th>Agreement Rate, %</th><th>Youden Index, <italic>r</italic></th><th>Positive LR</th><th>Negative LR</th></tr></thead><tbody><tr><td>55</td><td>57.14</td><td>100</td><td>100</td><td>68.42</td><td>77.78</td><td>0.57</td><td>—</td><td>0.43</td></tr><tr><td>57</td><td>71.43</td><td>100</td><td>100</td><td>76.47</td><td>85.19</td><td>0.71</td><td>—</td><td>0.29</td></tr><tr><td>60</td><td>85.71</td><td>92.31</td><td>92.31</td><td>85.71</td><td>88.89</td><td>0.78</td><td>11.14</td><td>0.15</td></tr><tr><td>63</td><td>92.86</td><td>76.92</td><td>81.25</td><td>90.91</td><td>85.19</td><td>0.70</td><td>4.02</td><td>0.09</td></tr><tr><td>65</td><td>92.86</td><td>53.85</td><td>68.42</td><td>87.50</td><td>74.07</td><td>0.47</td><td>2.01</td><td>0.13</td></tr><tr><td>70</td><td>100</td><td>15.38</td><td>56.00</td><td>100</td><td>59.29</td><td>0.15</td><td>1.18</td><td>0</td></tr></tbody></table><table-wrap-foot><fn id="table-fn5-1933719112459227"><p>Abbreviations: LR, likelihood ratio; PlGF, placental growth factor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table5-1933719112459227" position="float"><label>Table 5.</label><caption><p>Different Cutoff Points for Urinary PlGF and the Evaluated Index for Preeclampsia Diagnosis.</p></caption><graphic alternate-form-of="table5-1933719112459227" xlink:href="10.1177_1933719112459227-table5.tif"/><table><thead><tr><th>Cutoff Points, pg/mL</th><th>Sensitivity, %</th><th>Specificity, %</th><th>Positive Predictive Value, %</th><th>Negative Predictive Value, %</th><th>Agreement Rate, %</th><th>Youden Index, <italic>r</italic></th><th>Positive LR</th><th>Negative LR</th></tr></thead><tbody><tr><td>8</td><td>21.43</td><td>84.62</td><td>60.00</td><td>50.00</td><td>51.85</td><td>0.06</td><td>1.39</td><td>0.93</td></tr><tr><td>10</td><td>35.71</td><td>76.92</td><td>62.50</td><td>52.63</td><td>51.85</td><td>0.13</td><td>1.55</td><td>0.84</td></tr><tr><td>12</td><td>42.86</td><td>69.23</td><td>60.00</td><td>52.94</td><td>51.85</td><td>0.12</td><td>1.39</td><td>0.83</td></tr><tr><td>14</td><td>62.29</td><td>53.85</td><td>60.00</td><td>58.33</td><td>51.85</td><td>0.18</td><td>1.39</td><td>0.66</td></tr><tr><td>16</td><td>85.71</td><td>46.15</td><td>63.16</td><td>75.00</td><td>51.85</td><td>0.32</td><td>1.59</td><td>0.31</td></tr><tr><td>20</td><td>92.86</td><td>46.15</td><td>65.00</td><td>85.71</td><td>51.85</td><td>0.39</td><td>1.72</td><td>0.15</td></tr><tr><td>25</td><td>100</td><td>46.15</td><td>66.67</td><td>100</td><td>51.85</td><td>0.46</td><td>1.86</td><td>0</td></tr><tr><td>30</td><td>100</td><td>38.46</td><td>63.64</td><td>100</td><td>51.85</td><td>0.38</td><td>1.63</td><td>0</td></tr></tbody></table><table-wrap-foot><fn id="table-fn6-1933719112459227"><p>Abbreviations: LR, likelihood ratio; PlGF, placental growth factor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table6-1933719112459227" position="float"><label>Table 6.</label><caption><p>Different Cutoff Points for the Serum PlGF/sFlt-1 Ratio and the Evaluated Index for Preeclampsia Diagnosis.</p></caption><graphic alternate-form-of="table6-1933719112459227" xlink:href="10.1177_1933719112459227-table6.tif"/><table><thead><tr><th>Cutoff Points, pg/mL</th><th>Sensitivity, %</th><th>Specificity, %</th><th>Positive Predictive Value, %</th><th>Negative Predictive Value, %</th><th>Agreement Rate, %</th><th>Youden Index, <italic>r</italic></th><th>Positive LR</th><th>Negative LR</th></tr></thead><tbody><tr><td>0.10</td><td>57.14</td><td>100</td><td>100</td><td>68.42</td><td>77.78</td><td>0.57</td><td align="center">—</td><td>0.43</td></tr><tr><td>0.11</td><td>71.43</td><td>92.31</td><td>90.91</td><td>75.00</td><td>81.48</td><td>0.64</td><td>9.29</td><td>0.31</td></tr><tr><td>0.12</td><td>92.86</td><td>76.92</td><td>81.25</td><td>90.91</td><td>85.19</td><td>0.70</td><td>4.02</td><td>0.09</td></tr><tr><td>0.13</td><td>100</td><td>38.46</td><td>62.64</td><td>100</td><td>70.37</td><td>0.38</td><td>1.63</td><td>0</td></tr></tbody></table><table-wrap-foot><fn id="table-fn7-1933719112459227"><p>Abbreviations: LR, likelihood ratio; PlGF, placental growth factor; sFlt-1, antiangiogenic factor soluble fms-like tyrosine kinase 1.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table7-1933719112459227" position="float"><label>Table 7.</label><caption><p>Different Cutoff Points for the Urinary PlGF/sFlt-1 Ratio and the Evaluated Index for Preeclampsia Diagnosis.</p></caption><graphic alternate-form-of="table7-1933719112459227" xlink:href="10.1177_1933719112459227-table7.tif"/><table><thead><tr><th>Cutoff Points</th><th>Sensitivity, %</th><th>Specificity, %</th><th>Positive Predictive Value, %</th><th>Negative Predictive Value, %</th><th>Agreement Rate, %</th><th>Youden Index, <italic>r</italic></th><th>Positive LR</th><th>Negative LR</th></tr></thead><tbody><tr><td>0.010</td><td>21.43</td><td>84.62</td><td>60.00</td><td>50.00</td><td>51.85</td><td>0.06</td><td>1.39</td><td>0.93</td></tr><tr><td>0.015</td><td>50.00</td><td>69.23</td><td>63.64</td><td>56.25</td><td>59.26</td><td>0.19</td><td>1.63</td><td>0.72</td></tr><tr><td>0.020</td><td>78.57</td><td>46.15</td><td>61.11</td><td>66.67</td><td>62.96</td><td>0.25</td><td>1.46</td><td>0.46</td></tr><tr><td>0.025</td><td>92.86</td><td>46.15</td><td>65.00</td><td>85.71</td><td>70.37</td><td>0.39</td><td>1.72</td><td>0.15</td></tr><tr><td>0.050</td><td>100</td><td>38.46</td><td>63.64</td><td>100</td><td>70.37</td><td>0.38</td><td>1.63</td><td>0</td></tr></tbody></table><table-wrap-foot><fn id="table-fn8-1933719112459227"><p>Abbreviations: LR, likelihood ratio PlGF, placental growth factor; sFlt-1, antiangiogenic factor soluble fms-like tyrosine kinase 1.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table8-1933719112459227" position="float"><label>Table 8.</label><caption><p>Different Sensitivities and Specificities Using Podocyturia and Serum and Urinary PlGF Alone, in Parallel or in Series.</p></caption><graphic alternate-form-of="table8-1933719112459227" xlink:href="10.1177_1933719112459227-table8.tif"/><table><thead><tr><th/><th>Test Method</th><th>Sensitivity, %</th><th>Specificity, %</th></tr></thead><tbody><tr><td>1</td><td>Serum PlGF &lt;60 pg/mL</td><td>85.71</td><td>92.31</td></tr><tr><td>2</td><td>Urinary PlGF &lt;25 pg/mL</td><td>100</td><td>46.15</td></tr><tr><td>3</td><td>Podocyturia ≥1 cells/mL</td><td>100</td><td>76.92</td></tr><tr><td>1 and 2</td><td>In parallel</td><td>100</td><td>42.60</td></tr><tr><td>1 and 2</td><td>In series</td><td>85.71</td><td>95.86</td></tr><tr><td>2 and 3</td><td>In parallel</td><td>100</td><td>35.50</td></tr><tr><td>2 and 3</td><td>In series</td><td>100</td><td>87.57</td></tr><tr><td>1 and 3</td><td>In parallel</td><td>100</td><td>71.00</td></tr><tr><td>1 and 3</td><td>In series</td><td>85.71</td><td>98.22</td></tr></tbody></table><table-wrap-foot><fn id="table-fn9-1933719112459227"><p>Abbreviations: PlGF, placental growth factor.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="section13-1933719112459227"><title>Discussion</title><p>Preeclampsia is a hypertensive syndrome of pregnancy with consistent involvement of the kidney and is characterized by proteinuria and, frequently, edema.<sup><xref ref-type="bibr" rid="bibr19-1933719112459227">19</xref></sup> However, the source of proteinuria is still unclear. It is generally recognized that the injury of endothelial cells is the predominant renal injury in preeclampsia.<sup><xref ref-type="bibr" rid="bibr20-1933719112459227">20</xref></sup> Recent studies have provided novel insights into the role of podocyte injury in proteinuria and the development of preeclampsia.</p><p>The excretion of podocytes into the urine in various glomerular diseases is considered to result from the detachment of podocytes from the glomeruli and is closely linked to proteinuria.<sup><xref ref-type="bibr" rid="bibr21-1933719112459227">21</xref>,<xref ref-type="bibr" rid="bibr22-1933719112459227">22</xref></sup> Podocalyxin, the main podocyte surface antigen, has been used reliably in immunofluorescence for the detection of urinary podocytes.<sup><xref ref-type="bibr" rid="bibr18-1933719112459227">18</xref></sup> Based on these reports, we studied the podocyturia in our preeclamptic participants. The present results suggest that the number of urinary podocyte in women with preeclampsia is significantly higher than in women with gestational hypertension or normal pregnancies. Furthermore, the number of urinary podocytes is higher in women with gestational hypertension than in women with normal pregnancies, although this may be attributed to the elevated blood pressure. Moreover, podocyturia is positively correlated with ACR, renal function, and blood pressure and is inversely correlated with eGFR.</p><p>Although the mechanisms responsible for the emergence of the preeclampsia phenotype in women are poorly understood, it has been largely accepted to be associated with an abnormality in the levels of various angiogenic factors, including VEGF, PlGF, and the antiangiogenic factor sFlt-1, all of which are critical pathogenetic elements of preeclampsia. Podocytes secret VEGF and neuropilin, a VEGF receptor, are expressed on podocytes, thereby providing evidence that the effect of preeclampsia on podocyte health could even be the primary event.<sup><xref ref-type="bibr" rid="bibr23-1933719112459227">23</xref></sup> However, the cross talk between podocytes and endothelial cell remains to be investigated.<sup><xref ref-type="bibr" rid="bibr2-1933719112459227">2</xref></sup> Sugimoto et al<sup><xref ref-type="bibr" rid="bibr24-1933719112459227">24</xref></sup> reported that the intravenous infusion of sFlt-1 into normal healthy mice caused glomerular endotheliosis and proteinuria through a mechanism that was likely associated with the downregulation of nephrin, a specific protein of the podocyte slit diaphragm. The low serum and urinary levels of PlGF were associated with an increased risk for subsequent preeclampsia.<sup><xref ref-type="bibr" rid="bibr15-1933719112459227">15</xref>,<xref ref-type="bibr" rid="bibr25-1933719112459227">25</xref></sup> Several researchers have reported that circulating free VEGF and PlGF are decreased in preeclampsia due to their binding to the antagonistic receptor sFlt-1, present in elevated levels.<sup><xref ref-type="bibr" rid="bibr26-1933719112459227">26</xref><xref ref-type="bibr" rid="bibr27-1933719112459227"/>–<xref ref-type="bibr" rid="bibr28-1933719112459227">28</xref></sup> Other investigations suggest that the elevated levels of serum and plasma VEGF in patients with preeclampsia may also contribute to the extravasations of proteins and the subsequent development of proteinuria.<sup><xref ref-type="bibr" rid="bibr29-1933719112459227">29</xref><xref ref-type="bibr" rid="bibr30-1933719112459227"/><xref ref-type="bibr" rid="bibr31-1933719112459227"/>–<xref ref-type="bibr" rid="bibr32-1933719112459227">32</xref></sup> This study indicates that serum VEGF concentrations in women with preeclampsia are significantly higher than in women with normal pregnancies and are slightly higher than in women with gestational hypertension. However, there is no significant difference in the urinary VEGF concentrations. Elevated serum VEGF levels may be involved in the activation and dysfunction of endothelial cells.<sup><xref ref-type="bibr" rid="bibr33-1933719112459227">33</xref></sup> It is possible that the hyperdynamic circulation that characterizes the latent phase of preeclampsia causes vascular shear stress, which in turn increases the levels of circulating VEGF. Despite the increased serum levels of total VEGF, the levels of free-flowing VEGF may be decreased in preeclampsia compared to normal pregnancy.<sup><xref ref-type="bibr" rid="bibr31-1933719112459227">31</xref></sup> Thus, the decrease in the freely circulating levels of VEGF, rather than the increased total VEGF levels, may be involved in the pathogenesis of preeclampsia.<sup><xref ref-type="bibr" rid="bibr34-1933719112459227">34</xref></sup> Our detection of serum and urinary PlGF and sFlt-1 concentrations as well as their alterations among the 3 groups is consistent with previous work,<sup><xref ref-type="bibr" rid="bibr14-1933719112459227">14</xref>,<xref ref-type="bibr" rid="bibr15-1933719112459227">15</xref>,<xref ref-type="bibr" rid="bibr25-1933719112459227">25</xref>,<xref ref-type="bibr" rid="bibr27-1933719112459227">27</xref>,<xref ref-type="bibr" rid="bibr35-1933719112459227">35</xref>,<xref ref-type="bibr" rid="bibr36-1933719112459227">36</xref></sup> although the levels of these detection were lower than those reported in some literature.<sup><xref ref-type="bibr" rid="bibr14-1933719112459227">14</xref>,<xref ref-type="bibr" rid="bibr15-1933719112459227">15</xref></sup> The discrepancy may be produced by some factors as follows: the gestational age and the severity of preeclampsia; the time of preeclampsia onset; the ethnic difference; the situation of placenta and fetus from different patients which involve the secretion of VEGF, PlGF, and sFlt-1. In addition, the experimental conditions such as the length of storage time of the samples and the sensitivity of detective reagents, and so on may also contribute to the discrepancy. The elevation of sFlt-1 levels, which is well documented in preeclampsia, may disrupt the slit diaphragm proteins, thereby causing proteinuria.<sup><xref ref-type="bibr" rid="bibr3-1933719112459227">3</xref></sup> Gestational hypertension may be an intermediate stage that has some features of both normal pregnancy and preeclampsia. Furthermore, the correlation analysis may support the idea that the imbalance of serum and urinary VEGF, PlGF, and sFlt-1 induces podocyte injury and leads to proteinuria in preeclampsia. As kidney biopsies are rarelyperformed during preeclampsia, the development of noninvasive screening and diagnostic strategies is essential for the early detection of this disease. The ROC curves show that podocyturia, serum and urinary PlGF levels, and the PlGF/sFlt-1 ratio were superior to VEGF and sFlt-1 levels alone for identifying preeclampsia. Furthermore, the analysis of sensitivity and specificity found that higher sFlt-1 concentrations and lower PlGF levels increase the predictive value of podocyturia. The combination of podocyturia and/or PlGF may be helpful for aiding in the identification of preeclampsia. The PlGF/sFlt-1 ratio may also have utility as an indicator of preeclampsia.</p><p>Of course, the limitation should also be addressed. As the sample size was relatively small in this study, there may be little numerical discrepancy. Nevertheless, the overall trend of the results were consistent with literature,<sup><xref ref-type="bibr" rid="bibr14-1933719112459227">14</xref>,<xref ref-type="bibr" rid="bibr15-1933719112459227">15</xref>,<xref ref-type="bibr" rid="bibr25-1933719112459227">25</xref>,<xref ref-type="bibr" rid="bibr26-1933719112459227">26</xref>,<xref ref-type="bibr" rid="bibr36-1933719112459227">36</xref></sup> which proved that the analyses from the small sample size was still worthy of credible so that the generated conclusion was also meaningful.</p><p>In conclusion, deregulation of pro- and antiangiogenic factors and subsequent podocyte injury may represent a possible mechanism for the development of proteinuria in preeclampsia. Podocyturia, PlGF, and PlGF/sFlt-1 ratios may provide clue for discovering early diagnostic markers for preeclampsia. Further prospective studies of larger cohorts are needed to explore this in detail.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by a Grant from the Major State Basic Research Development Program of China (973 Program; No. 2012CB517700). The authors would like to thank the staff at the Department of Gynecology and Obstetrics, the Fifth People’s Hospital of Shanghai, Fudan University, for their help with sample collection.</p></ack><fn-group><fn fn-type="other" id="fn1-1933719112459227"><label>Authors’ Note</label><p>The work reported was done in the Fifth People’s Hospital of Shanghai and Huashan Hospital, Fudan University, Shanghai, China.</p></fn><fn fn-type="conflict" id="fn2-1933719112459227"><label>Declaration of Conflicting Interests</label><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure" id="fn3-1933719112459227"><label>Funding</label><p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Grant from the <grant-sponsor>Major State Basic Research Development Program of China</grant-sponsor><?release-delay 12|0?> (973 Program) (No. <grant-num>2012CB517700</grant-num>). </p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1933719112459227"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sibai</surname><given-names>B</given-names></name><name><surname>Dekker</surname><given-names>G</given-names></name><name><surname>Kupferminc</surname><given-names>M</given-names></name></person-group>. <article-title>Pre-eclampsia</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>365</volume>(<issue>9461</issue>):<fpage>785</fpage>–<lpage>799</lpage>.</citation></ref><ref id="bibr2-1933719112459227"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collino</surname><given-names>F</given-names></name><name><surname>Bussolati</surname><given-names>B</given-names></name><name><surname>Gerbaudo</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells</article-title>. <source>Am J Physiol Renal Physiol</source>. <year>2008</year>;<volume>294</volume>(<issue>5</issue>):<fpage>F1185</fpage>–<lpage>F1194</lpage>.</citation></ref><ref id="bibr3-1933719112459227"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garovic</surname><given-names>VD</given-names></name><name><surname>Wagner</surname><given-names>SJ</given-names></name><name><surname>Petrovic</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia</article-title>. <source>Nephrol Dial Transplant</source>. <year>2007</year>;<volume>22</volume>(<issue>4</issue>):<fpage>1136</fpage>–<lpage>1143</lpage>.</citation></ref><ref id="bibr4-1933719112459227"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Achenbach</surname><given-names>J</given-names></name><name><surname>Mengel</surname><given-names>M</given-names></name><name><surname>Tossidou</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases</article-title>. <source>Nephrol Dial Transplant</source>. <year>2008</year>;<volume>23</volume>(<issue>10</issue>):<fpage>3138</fpage>–<lpage>3145</lpage>.</citation></ref><ref id="bibr5-1933719112459227"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petermann</surname><given-names>A</given-names></name><name><surname>Floege</surname><given-names>J</given-names></name></person-group>. <article-title>Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity</article-title>. <source>Nephron Clin Pract</source>. <year>2007</year>;<volume>106</volume>(<issue>2</issue>):<fpage>c61</fpage>–<lpage>c66</lpage>.</citation></ref><ref id="bibr6-1933719112459227"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Petermann</surname><given-names>A</given-names></name><name><surname>Kunter</surname><given-names>U</given-names></name><name><surname>Rong</surname><given-names>S</given-names></name><name><surname>Shankland</surname><given-names>SJ</given-names></name><name><surname>Floege</surname><given-names>J</given-names></name></person-group>. <article-title>Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria</article-title>. <source>J Am Soc Nephrol</source>. <year>2005</year>;<volume>16</volume>(<issue>6</issue>):<fpage>1733</fpage>–<lpage>1741</lpage>.</citation></ref><ref id="bibr7-1933719112459227"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Yanagihara</surname><given-names>T</given-names></name><name><surname>Kihara</surname><given-names>I</given-names></name><name><surname>Higashi</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><name><surname>Kajita</surname><given-names>T</given-names></name></person-group>. <article-title>Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury</article-title>. <source>J Am Soc Nephrol</source>. <year>2005</year>;<volume>16</volume>(<issue>2</issue>):<fpage>408</fpage>–<lpage>416</lpage>.</citation></ref><ref id="bibr8-1933719112459227"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skoberne</surname><given-names>A</given-names></name><name><surname>Konieczny</surname><given-names>A</given-names></name><name><surname>Schiffer</surname><given-names>M</given-names></name></person-group>. <article-title>Glomerular epithelial cells in the urine: what has to be done to make them worthwhile?</article-title> <source>Am J Physiol Renal Physiol</source>. <year>2009</year>;<volume>296</volume>(<issue>2</issue>):<fpage>F230</fpage>–<lpage>F241</lpage>.</citation></ref><ref id="bibr9-1933719112459227"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garovic</surname><given-names>VD</given-names></name><name><surname>Wagner</surname><given-names>SJ</given-names></name><name><surname>Turner</surname><given-names>ST</given-names></name><etal/></person-group>. <article-title>Urinary podocyte excretion as a marker for preeclampsia</article-title>. <source>Am J Obstet Gynecol</source>. <year>2007</year>;<volume>196</volume>(<issue>4</issue>):320.<fpage>e1</fpage>–<lpage>320</lpage>.e7.</citation></ref><ref id="bibr10-1933719112459227"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aita</surname><given-names>K</given-names></name><name><surname>Etoh</surname><given-names>M</given-names></name><name><surname>Hamada</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Acute and transient podocyte loss and proteinuria in preeclampsia</article-title>. <source>Nephron Clin Pract</source>. <year>2009</year>;<volume>112</volume>(<issue>2</issue>):<fpage>c65</fpage>–<lpage>c70</lpage>.</citation></ref><ref id="bibr11-1933719112459227"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karumanchi</surname><given-names>SA</given-names></name><name><surname>Lindheimer</surname><given-names>MD</given-names></name></person-group>. <article-title>Preeclampsia and the kidney: footprints in the urine</article-title>. <source>Am J Obstet Gynecol</source>. <year>2007</year>;<volume>196</volume>(<issue>4</issue>):<fpage>287</fpage>–<lpage>288</lpage>.</citation></ref><ref id="bibr12-1933719112459227"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>L</given-names></name><name><surname>LaMarca</surname><given-names>BB</given-names></name><name><surname>Fournier</surname><given-names>L</given-names></name><name><surname>Bain</surname><given-names>J</given-names></name><name><surname>Cockrell</surname><given-names>K</given-names></name><name><surname>Granger</surname><given-names>JP</given-names></name></person-group>. <article-title>Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion</article-title>. <source>Hypertension</source>. <year>2006</year>;<volume>47</volume>(<issue>3</issue>):<fpage>615</fpage>–<lpage>618</lpage>.</citation></ref><ref id="bibr13-1933719112459227"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>RJ</given-names></name><name><surname>Lam</surname><given-names>C</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Soluble endoglin and other circulating antiangiogenic factors in preeclampsia</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>(<issue>10</issue>):<fpage>992</fpage>–<lpage>1005</lpage>.</citation></ref><ref id="bibr14-1933719112459227"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>RJ</given-names></name><name><surname>Maynard</surname><given-names>SE</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Circulating angiogenic factors and the risk of preeclampsia</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>350</volume>(<issue>7</issue>):<fpage>672</fpage>–<lpage>683</lpage>.</citation></ref><ref id="bibr15-1933719112459227"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>RJ</given-names></name><name><surname>Thadhani</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Urinary placental growth factor and risk of preeclampsia</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>293</volume>(<issue>1</issue>):<fpage>77</fpage>–<lpage>85</lpage>.</citation></ref><ref id="bibr16-1933719112459227"><label>16</label><citation citation-type="journal">. <article-title>Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy</article-title>. <source>Am J Obstet Gynecol</source>. <year>2000</year>;<volume>183</volume>(<issue>1</issue>):<fpage>S1</fpage>–<lpage>S22</lpage>.</citation></ref><ref id="bibr17-1933719112459227"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Ushiyama</surname><given-names>C</given-names></name><name><surname>Hirokawa</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis</article-title>. <source>Nephrol Dial Transplant</source>. <year>2002</year>;<volume>17</volume>(<issue>5</issue>):<fpage>798</fpage>–<lpage>802</lpage>.</citation></ref><ref id="bibr18-1933719112459227"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Yanagihara</surname><given-names>T</given-names></name><name><surname>Kihara</surname><given-names>I</given-names></name></person-group>. <article-title>Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schonlein-Henoch purpura nephritis</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2007</year>;<volume>2</volume>(<issue>2</issue>):<fpage>231</fpage>–<lpage>238</lpage>.</citation></ref><ref id="bibr19-1933719112459227"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>DM</given-names></name></person-group>. <article-title>Role of the renin-angiotensin system in the pathogenesis of preeclampsia</article-title>. <source>Am J Physiol Renal Physiol</source>. <year>2005</year>;<volume>288</volume>(<issue>4</issue>):<fpage>F614</fpage>–<lpage>625</lpage>.</citation></ref><ref id="bibr20-1933719112459227"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strevens</surname><given-names>H</given-names></name><name><surname>Wide-Swensson</surname><given-names>D</given-names></name><name><surname>Hansen</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Glomerular endotheliosis in normal pregnancy and pre-eclampsia</article-title>. <source>BJOG</source>. <year>2003</year>;<volume>110</volume>(<issue>9</issue>):<fpage>831</fpage>–<lpage>836</lpage>.</citation></ref><ref id="bibr21-1933719112459227"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lemley</surname><given-names>KV</given-names></name><name><surname>Lafayette</surname><given-names>RA</given-names></name><name><surname>Safai</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Podocytopenia and disease severity in IgA nephropathy</article-title>. <source>Kidney Int</source>. <year>2002</year>;<volume>61</volume>(<issue>4</issue>):<fpage>1475</fpage>–<lpage>1485</lpage>.</citation></ref><ref id="bibr22-1933719112459227"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Kawagoe</surname><given-names>Y</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy</article-title>. <source>Am J Kidney Dis</source>. <year>2005</year>;<volume>45</volume>(<issue>1</issue>):<fpage>48</fpage>–<lpage>53</lpage>.</citation></ref><ref id="bibr23-1933719112459227"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>SJ</given-names></name><name><surname>Xing</surname><given-names>CY</given-names></name><name><surname>Whittle</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo</article-title>. <source>Clin Sci (Lond)</source>. <year>2001</year>;<volume>101</volume>(<issue>4</issue>):<fpage>439</fpage>–<lpage>446</lpage>.</citation></ref><ref id="bibr24-1933719112459227"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Hamano</surname><given-names>Y</given-names></name><name><surname>Charytan</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>15</issue>):<fpage>12605</fpage>–<lpage>12608</lpage>.</citation></ref><ref id="bibr25-1933719112459227"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thadhani</surname><given-names>R</given-names></name><name><surname>Mutter</surname><given-names>WP</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>2</issue>):<fpage>770</fpage>–<lpage>775</lpage>.</citation></ref><ref id="bibr26-1933719112459227"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name><name><surname>Karumanchi</surname><given-names>SA</given-names></name></person-group>. <article-title>Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia</article-title>. <source>Hypertension</source>. <year>2005</year>;<volume>46</volume>(<issue>5</issue>):<fpage>1077</fpage>–<lpage>1085</lpage>.</citation></ref><ref id="bibr27-1933719112459227"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berkane</surname><given-names>N</given-names></name><name><surname>Lefevre</surname><given-names>G</given-names></name><name><surname>Hertig</surname><given-names>A</given-names></name></person-group>. <article-title>Angiogenic factors in preeclampsia: so complex, so simple?</article-title> <source>Nephrol Dial Transplant</source>. <year>2007</year>;<volume>22</volume>(<issue>10</issue>): <fpage>2753</fpage>–<lpage>2756</lpage>.</citation></ref><ref id="bibr28-1933719112459227"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawfield</surname><given-names>A</given-names></name><name><surname>Freedman</surname><given-names>BI</given-names></name></person-group>. <article-title>Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection</article-title>. <source>Ther Adv Cardiovasc Dis</source>. <year>2009</year>;<volume>3</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>73</lpage>.</citation></ref><ref id="bibr29-1933719112459227"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>PN</given-names></name><name><surname>Krasnow</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name><name><surname>Yeo</surname><given-names>KT.</given-names></name></person-group> <article-title>Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia</article-title>. <source>Obstet Gynecol</source>. <year>1995</year>;<volume>86</volume>(<issue>5</issue>):<fpage>815</fpage>–<lpage>821</lpage>.</citation></ref><ref id="bibr30-1933719112459227"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>A</given-names></name><name><surname>Aitkenhead</surname><given-names>M</given-names></name><name><surname>Caldwell</surname><given-names>C</given-names></name><name><surname>McCracken</surname><given-names>G</given-names></name><name><surname>Wilson</surname><given-names>D</given-names></name><name><surname>McClure</surname><given-names>N</given-names></name></person-group>. <article-title>Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy</article-title>. <source>Hypertension</source>. <year>2000</year>;<volume>36</volume>(<issue>6</issue>):<fpage>965</fpage>–<lpage>969</lpage>.</citation></ref><ref id="bibr31-1933719112459227"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bosio</surname><given-names>PM</given-names></name><name><surname>Wheeler</surname><given-names>T</given-names></name><name><surname>Anthony</surname><given-names>F</given-names></name><name><surname>Conroy</surname><given-names>R</given-names></name><name><surname>O'Herlihy</surname><given-names>C</given-names></name><name><surname>McKenna</surname><given-names>P</given-names></name></person-group>. <article-title>Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance</article-title>. <source>Am J Obstet Gynecol</source>. <year>2001</year>;<volume>184</volume>(<issue>2</issue>):<fpage>146</fpage>–<lpage>152</lpage>.</citation></ref><ref id="bibr32-1933719112459227"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munaut</surname><given-names>C</given-names></name><name><surname>Lorquet</surname><given-names>S</given-names></name><name><surname>Pequeux</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast</article-title>. <source>Hum Reprod</source>. <year>2008</year>;<volume>23</volume>(<issue>6</issue>):<fpage>1407</fpage>–<lpage>1415</lpage>.</citation></ref><ref id="bibr33-1933719112459227"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akercan</surname><given-names>F</given-names></name><name><surname>Cirpan</surname><given-names>T</given-names></name><name><surname>Terek</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>The immunohistochemical evaluation of VEGF in placenta biopsies of pregnancies complicated by preeclampsia</article-title>. <source>Arch Gynecol Obstet</source>. <year>2008</year>;<volume>277</volume>(<issue>2</issue>):<fpage>109</fpage>–<lpage>114</lpage>.</citation></ref><ref id="bibr34-1933719112459227"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheppard</surname><given-names>SJ.</given-names></name><name><surname>Khalil</surname><given-names>RA</given-names></name></person-group>. <article-title>Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy</article-title>. <source>Cardiovasc Hematol Disord Drug Targets</source>. <year>2010</year>;<volume>10</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>52</lpage>.</citation></ref><ref id="bibr35-1933719112459227"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hladunewich</surname><given-names>M</given-names></name><name><surname>Karumanchi</surname><given-names>SA</given-names></name><name><surname>Lafayette</surname><given-names>R</given-names></name></person-group>. <article-title>Pathophysiology of the clinical manifestations of preeclampsia</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2007</year>;<volume>2</volume>(<issue>3</issue>):<fpage>543</fpage>–<lpage>549</lpage>.</citation></ref><ref id="bibr36-1933719112459227"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Troisi</surname><given-names>R</given-names></name><name><surname>Braekke</surname><given-names>K</given-names></name><name><surname>Harsem</surname><given-names>NK</given-names></name><name><surname>Hyer</surname><given-names>M</given-names></name><name><surname>Hoover</surname><given-names>RN</given-names></name><name><surname>Staff</surname><given-names>AC.</given-names></name></person-group> <article-title>Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies</article-title>. <source>Am J Obstet Gynecol</source>. <year>2008</year>;<volume>199</volume>(<issue>6</issue>):653.e1- 653.e10.</citation></ref></ref-list></back></article>